Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're new here. I've been here for over 10+ years. GL kid
Thanks, flipper44 for updates. In my opinion, all these patents from other countries does mean a crap while the DCVAX-D sitting on the shelf and collecting dust.
I was hoping for some kind of combo trials, but per last 10K LP put the cold water on this idea. This created a great opportunity for MMs to go after NWBO. If you cannot handle multi-tasking how on earth, you are able to handle multi cancer treatment indications.
We need Combo trials to show some kind of financial upfront so MMs cannot easily manipulate the PPS. As simple as that.
I do not like what i said above but the reality is what it is.
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
Vandana Singh
(Benzinga Newswire)
Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.
The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion’s closing market price of $10.64 on March 18, 2024.
Related Content: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Says AstraZeneca Is Favorably Positioned.
Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion.
AstraZeneca will acquire the cash, cash equivalents, and short-term investments on Fusion’s balance sheet, totaling $234 million as of December 31, 2023.
The acquisition marks a significant step forward for AstraZeneca in delivering on its ambition to transform cancer treatment and patient outcomes by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
Radioconjugates (RCs) have emerged as a promising modality in cancer treatment over recent years.
These medicines deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides, or small molecules.
This approach has many potential advantages compared to traditional radiotherapy, including minimizing damage to healthy cells and enabling access to inaccessible tumors through external beam radiation.
This acquisition complements AstraZeneca’s oncology portfolio by adding the Fusion pipeline of RCs, including the company’s most advanced program, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
FPI-2265 targets prostate-specific membrane antigen (PSMA), a protein highly expressed in mCRPC, and is currently in a Phase 2 trial.
Most recently, Bristol Myers Squibb & Co (NYSE:BMY) acquired RayzeBio Inc (NASDAQ:RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
Also, last year, Eli Lilly And Co (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. for $12.50 per share in cash, an aggregate of approximately $1.4 billion.
Price Action: FUSN shares are up 98.5% at $21.12 during the premarket session on the last check Tuesday.
Photo via Wikimedia Commons
Copyright notice: © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Hey Einstein, NWBO is a PRE REVENU company ie no revenu.
How do you think they pay the bills?
Patents.
Regulatory agency submissionS.
Employees.
Listing cost (OTC).
Consultants
Auditors
Etc…
Let me type really slow for you. The CEO/CFO Linda is selling company outstanding shares. She has sold 20 million shares since the 1st of the year. That's why we are down 30% in the past 3 months. By the way she has not brought any personal shares either. Not that she has to she has a ton of options. But, it would be good for investors confidence. Those are the Facts! See Captain obvious last post!
Linda hasn’t sold any of her shares.
MM are not the ones bringing this down. It's Linda selling shares day after day. Let's hope she's done for now.
That DCVax-Direct patent (aka partially matured), for treating solid tumors, which expires in June 2036, has now been granted in at least the following countries:
AU2016286112A1
2023-02-16
Granted (Australia)
2021-09-21
US11124768B2
Granted (United States)
JP2021191885A
2021-12-22
Granted (Japan)
IN201847003183
March 18, 2024
Granted (India)
Hey spartex, Pamela and I are in DC this week. We came up for our 10th Anniversary. Doing the tourist thing
03/19/24 - 1,193,316,128
03/15/24 - 1,193,166,128
03/14/24 - 1,192,908,369
03/10/23 - 1,192,237,685
03/07/24 - 1,190,170,308
02/29/24 - 1,189,970,308
02/27/24 - 1,188,836,983
02/22/24 - 1,188,731,708
02/17/24 - 1,187,812,280
02/14/24 - 1,186,753,180
02/13/24 - 1,186,425,305
01/30/24 - 1,185,680,827
01/27/24 - 1,185,128,327
01/25/24 - 1,182,971,840
01/24/24 - 1,182,454,590
01/23/24 - 1,182,433,108
01/19/24 - 1,181,833,108
01/09/24 - 1,181,176,418
01/04/24 - 1,175,459,031
01/03/24 - 1,173,563,502
2023:
12/23/23 - 1,172,382,472
01/06/23 - 1,061,044,165
2023 Detail:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173492032
2022:
12/21/22 - 1,058,132,006
01/22/22 - 949,180,606
2022 Detail:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170751056;
2021:
12/31/21 - 947,621,531
01/12/21 - 822,825,147
2020:
12/31/20 - 822,716,397
01/27/20 - 625,187,160
2020-2021 Detail:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167328119;
Shares outstanding from
https://www.otcmarkets.com/stock/NWBO/quote
That patent from India posted by axel extends its listing to most hemispheres not just India Did l read it wrong!??
BUY OUT = +1300% to where their shares traded 5 months ago and 2800% to where their shares traded 16 month ago
Fusion Pharma only have a Ph 2 trial :
Gemini :
As of today, March 19, 2024, Fusion Pharmaceuticals does not have any drugs that are approved by the US Food and Drug Administration (FDA). However, their pipeline includes several drugs in various stages of clinical trials. Their most advanced drug is FPI-2265, which is currently in a Phase 2 trial for the treatment of metastatic castration-resistant prostate cancer.
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
By Jamie Chisholm
(MarketWatch) -- AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
Fusion, whose shares trade in New York, is involved in radiopharmaceuticals, a rapidly growing area of cancer treatment that targets specific organs, tissues or cells within the human body.
"The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments," said AstraZeneca.
Cambridge-based AstraZeneca (UK:AZN) (AZN) said it would pay $21.00 per share in cash for Fusion's stock (FUSN), plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.
Fusion's shares closed Monday at $10.64, having already risen 165% over the past 12 months as analysts warmed to the sector and pointed to Fusion as a likely takeover target.
The deal follows AstraZeneca's $1 billion agreement last week to buy Amolyt, a French rare diseases start-up.
"Between thirty and fifty per cent of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of Fusion furthers our ambition to transform this aspect of care with next-generation radioconjugates," said Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca.
-Jamie Chisholm
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
$ nice Office india https://patentscope.wipo.int/search/en/detail.jsf?docId=IN327426168
I have no doubt LP has ethics. Your employer on the other hand, has no ethics or morals. It’s almost shocking that any organization could try to drive a company trying to cure Cancer out of business. Your postings are an integral part of that organization trying to push falsehoods.
Interesting:
$NWBO Miracle of Miracles - 1st time in 2 years of tracking this data...NO Failures-to-Deliver for 2H February!!! Zero, nada, zip. hmmm.... pic.twitter.com/hgn8rYgEfV
— Roberto (@rkawong66) March 18, 2024
I added at the discounted price.
If the sp dips lower I’ll keep adding.
Go big or go home!
The volume being over 2M shares today makes me wonder if short covering at reduced prices is going on since we are close to UK approval related news.
Could also be other bargain hunters acting on the cheap shares.
Phase 1 trials are when dosage parameters are investigated for tolerance, adverse reactions and other side effects.
theorysuit,
You are the one being scorned by MHRA because the Specials program offers promising unproven treatments to those who can find a way to afford them precisely because it is ethical to do so and that includes DCVax-L. Not only are they offering this but the leading neuro oncologist in the UK is on record as stating that he wants this L treatment for all of his patients.
Now who to believe… hmmm… theorysuit the crass anonymous message board poster with obvious animosity towards NWBO investors who won’t part easily with their shares or the highly respected Dr. Keyoumars Ashkan, Dr. Linda Liau and others who support getting this treatment to patients ASAP?; ). I think I’ll go with those well known doctors who actually want and KNOW what’s best for their patients vs the anonymous poster who only bad mouths the 28 year effort by a company and those working with them to bring a potential pathway for a cure to various solid tumor cancers and beyond to the forefront of clinical practice. Very easy choice at this poker table forum; ). Best wishes.
Surviving Marker Maker manipulation and decades of FUD to get to this point is quite the achievement. Thankfully we have Linda Powers and the rest of management or else I doubt we would have made this far.
We all know OS is the gold standard. Overall, NWBO has survived, and will survive the deceptive tactics being displayed on social media sites and online message boards. Once MAA is granted there’s nothing stopping DCVax. 💪
Sorry bro I have one boss and that's my wife. Go ahead and die on the shield for this POS company. That's honorable and stupid at the same time. Hopefully it is a small part of your portfolio. At least you will what you think are ETHICS ETHICS ETHICS because these company doesn't. LMFAO.
What would make you think this questionable company has ETHICS?
Ethics, Ethics, Ethics, I will sacrifice my investment if necessary. You boss is a total POS. ESAD.
Some of your favorite posters in that
Club. Skitahoe, doclogic, ilovetech, flipper, captain obvious all in that AARP club. Others too probably I missed. Not sure how that is total BS. Get rich or die tryin....RIP
There are plenty of Doctors that follow this stock and DCVax-L and they cannot wait until it is approved. FINALLY there will be an option. Another treatment that could provide an olive branch for life. The MHRA process is 150 days from December plus potentially a clock off per period. IMO definitely before 3rd quarter. Your AARP analogy is total bullshit. Soon the share price will drift up.
You talking about the parrot who kept repeating the 70 dr journal? Not sure he was able to call out any BS. You are better off putting this money into a legit company where it has a chance to succeed without all the piss poor execution and excuses you got here. What happens here if you hold long enough, you get put in AARP and Medicare while waiting.
Well Bala already rode off into the sunset. He was a great guy. Called out the bs when he saw it. Now I wonder when the others will finally call it quits. It is not too much longer before this stock hits $.4x and maybe lower. I’m holding my remaining shares just in case a miracle happens but I think lawsuit get dismissed and then even with approval still under $1. Oh well
But the pumpers argue that it would be unethical to not give patients an unproven drug. Lmfao. That's why you run a double blind trial.....to prove that is does work. Their arguments are lame af. Unethical....smfh. Now you have a poorly designed trial with dirty af data. A journal folks doesn't make it any better or guarantee approval. Sorry it doesn't work that way unfortunately....you will learn soon enough. LP going to string you along and find the next excuse to distract you all.
Early trial results from six patients with recurrent glioblastoma may be a promising step towards developing cell therapies for solid tumors
https://www.pennmedicine.org/news/news-releases/2024/march/dual-target-cell-therapy-appears-to-shrink-brain-tumors
Targeting two brain tumor-associated proteins—rather than one—with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma
Others still seem to think that targeting two proteins is enough
Thats why DCVax is superior, targeting the full spectrum of antigens on the tumor
.
That’s why we brought a gallon jug
GuruGary, from now on can you please put bullet points above your posts. Thanks.
And what you say about his company
Is what you say about society
Catch the witness
Catch the wit
Catch the spirit
Catch the spit
LOL why is this not 0001 by now! but i love the daily! Years! and multi years. of the same Ikshi! good lord. whens it gonna end! :):):)..been here myself since 2009. one good run! it was great!
I yield my remaining time to this post.
Lol
Who wants to take a bet that nothing will happen in 3 days
Let’s see who has the conviction to change their login ID after 3 days
Thanks a lot NotSure2!!
great for the curcumin comminity
India. DCVax-Direct Patent Grant. For solid Tumors. Goes out to about 2035 or 2036.
$NWBO patent granted on March 18, 2024 - IN201847003183 🇮🇳: "Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response"https://t.co/8Sbs08Ndd5 pic.twitter.com/TuW6Ad6e9P
— Henry (@HenryMuney) March 18, 2024
Mmmmm SCIENCE!!
Doc, I have to repeat this again because I feel this is one of the most exciting parts. For this combo trial as shown in the figure, tumor-associated macrophage (green dots) is the culprit in suppressing ant-tumor immune response and Plx3397 as shown in other publications can… pic.twitter.com/Uszv7Exrzs
— d_stock (@d_stock07734) March 18, 2024
No! But I did notice another COUNTRY awarded NWBO a new patent! Did you see that?
skitahoe,
Both flipper44 and I agreed that ICT-107 should have been approved for a subset of patients. No go and those patients were left without something that was likely to help with their particular situation because of it. The limited approval may not have been able to make the company lots of money but at least some patients would have started having the opportunity for better outcomes. This is the same line of thinking that limited access to experimental treatments like L, where safety is not a concern, should be made available at a regulated price equal to about 50% of the cost of SOC and paid for with set asides for such treatments and patient funds based on reasonable ability to pay. Best wishes.
Anyone else notice that there is a NEW "KEYWORD" every week?
Followers
|
1604
|
Posters
|
|
Posts (Today)
|
24
|
Posts (Total)
|
679564
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |